Evolus, Inc.
NGM: EOLSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Evolus, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get EOLS Z-Score →About Evolus, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
📊 Fundamental Analysis
Evolus, Inc. demonstrates a profit margin of -17.4%, which is below the sector average, suggesting competitive pressure.
The company recently reported 14.4% revenue growth, which is above average for the Healthcare sector.
At a current price of $4.27, EOLS currently trades near the bottom of its 52-week range (5%), indicating potential value or weakness (Range: $3.86 - $12.28).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$277.81M
Trailing P/E
--
Forward P/E
17.79
Beta (5Y)
1.00
52W High
$12.28
52W Low
$3.86
Avg Volume
1.22M
Day High
Day Low